Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$0.65 +2.3%	$0.91	$0.52 ▼ $5.39	$7.12M	0.12	611,514 shs	17,982 shs
CLSD Clearside Biomedical	$0.41 +1.0%	$0.61	$0.29 ▼ $1.65	$31.64M	2.08	880,619 shs	364,782 shs
DYAI Dyadic International	$0.85 +8.8%	$0.96	$0.71 ▼ $2.20	$28.26M	0.89	132,437 shs	253,904 shs
OKUR OnKure Therapeutics	$2.83 +4.4%	$2.40	$1.70 ▼ $20.00	$36.61M	0.4	131,212 shs	59,581 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	+2.25%	+3.15%	-5.81%	-40.26%	-88.09%
CLSD Clearside Biomedical	+1.04%	-3.74%	-30.39%	-52.82%	-59.68%
DYAI Dyadic International	+8.83%	+13.59%	-22.73%	-14.64%	-35.61%
OKUR OnKure Therapeutics	+4.43%	+11.86%	+18.91%	+31.63%	+282,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCLI Brainstorm Cell Therapeutics	2.3406 of 5 stars	0.0	5.0	4.7	2.1	0.8	0.6
CLSD Clearside Biomedical	1.8665 of 5 stars	4.1	3.0	0.0	0.6	0.0	0.0
DYAI Dyadic International	3.3385 of 5 stars	3.5	5.0	0.0	2.2	3.3	0.0
OKUR OnKure Therapeutics	3.1995 of 5 stars	3.6	0.0	0.0	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
CLSD Clearside Biomedical	2.17	Hold	$4.20	931.43% Upside
DYAI Dyadic International	3.00	Buy	$6.00	605.88% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,042.52% Upside

Current Analyst Ratings Breakdown

Latest BCLI, DYAI, CLSD, and OKUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
CLSD Clearside Biomedical	$1.66M	19.26	N/A	N/A	($0.62) per share	-0.66
DYAI Dyadic International	$3.49M	8.81	N/A	N/A	($0.01) per share	-85.00
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.10	N/A	N/A	N/A	N/A	N/A	-519.50%	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)

Latest BCLI, DYAI, CLSD, and OKUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
CLSD Clearside Biomedical	N/A	3.87	3.87
DYAI Dyadic International	5.40	2.02	2.02
OKUR OnKure Therapeutics	N/A	11.13	11.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
CLSD Clearside Biomedical	18.75%
DYAI Dyadic International	27.95%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
CLSD Clearside Biomedical	6.70%
DYAI Dyadic International	29.50%
OKUR OnKure Therapeutics	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	13.20 million	N/A

BCLI, DYAI, CLSD, and OKUR Headlines

Recent News About These Companies

Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33

August 22 at 2:15 AM | americanbankingnews.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19, 2025 | finance.yahoo.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19, 2025 | finance.yahoo.com

Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings

August 16, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)

August 15, 2025 | theglobeandmail.com

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

August 12, 2025 | msn.com

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 12, 2025 | globenewswire.com

OKUR OnKure Therapeutics, Inc.

June 12, 2025 | seekingalpha.com

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

June 3, 2025 | tipranks.com

Insider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of Stock

May 20, 2025 | insidertrades.com

OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 Shares

May 15, 2025 | insidertrades.com

Major Shareholder Sells Thousands of OnKure Therapeutics Shares!

May 14, 2025 | tipranks.com

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

May 9, 2025 | tipranks.com

OnKure increased R&D spending in 1Q with drug trials underway

May 7, 2025 | bizwest.comB

OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | finanznachrichten.de

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock News

April 30, 2025 | gurufocus.com

OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Charts

April 16, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, DYAI, CLSD, and OKUR Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.65 +0.01 (+2.25%)

As of 08/22/2025 03:21 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Clearside Biomedical NASDAQ:CLSD

$0.41 +0.00 (+1.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.40 -0.01 (-3.00%)

As of 08/22/2025 07:54 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dyadic International NASDAQ:DYAI

$0.85 +0.07 (+8.83%)

As of 08/22/2025 04:00 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

OnKure Therapeutics NASDAQ:OKUR

$2.83 +0.12 (+4.43%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.82 -0.01 (-0.35%)

As of 08/22/2025 07:57 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time